Common Blood Thinner May Slow Cognitive Decline

Karolinska Institutet Study Tracks 7,300 Patients

The nationwide study examined registry data from over 7,300 individuals diagnosed with Alzheimer’s disease who also had atrial fibrillation (AFib)—an irregular heart rhythm—before their dementia diagnosis. Investigators utilized linked national Swedish registries, including the SveDem cognitive disorders register, tracking metrics such as Mini-Mental State Examination (MMSE) scores, prescription records, and hospital visits for up to five years, according to findings detailed by study authors.

To establish fair comparisons, researchers grouped participants into three distinct cohorts: individuals not taking blood thinners, patients taking the older anticoagulant warfarin, and those prescribed newer NOAC medications. Statistical adjustments accounted for baseline variables like age, co-existing health conditions, and concurrent drug use across the matched groups.

NOACs Versus Warfarin: Cognitive and Safety Outcomes

Patients treated with NOACs demonstrated a modest yet statistically significant slowing in cognitive decline compared to both warfarin users and untreated individuals, with a difference corresponding to just over 0.2 MMSE points per year. While the annual shift appears small for an individual, lead co-author Nanbo Zhu noted that over an extended timeframe, this effect can influence how overall cognitive function develops.

In addition to cognitive preservation, NOAC users exhibited lower risks of stroke, death, and bone fractures than non-users. Warfarin users also experienced fewer strokes and deaths than untreated patients, but faced a heightened risk of major bleeding. When compared directly against warfarin, NOACs delivered fewer strokes and reduced major bleeding incidents.

Did You Know?

According to study co-author Maria Eriksdotter, professor at the Department of Neurobiology, Care Sciences and Society at the Karolinska Institutet, and senior consultant in geriatric medicine at Karolinska University Hospital, blood thinners may support brain health by improving blood flow and reducing small-scale damage in the brain.

Addressing Silent Strokes Caused by Atrial Fibrillation

AFib causes the upper chambers of the heart to quiver rather than beat effectively, which allows blood to pool and form microscopic clots known as micro-emboli, according to Bhaskar Semitha, MD, a cardiothoracic surgeon with ClinicSpots who was not involved in the research. These micro-emboli pump continuously into the brain, causing silent strokes that damage small blood vessels, starve brain tissue of oxygen, and accelerate cognitive decline.

Semitha noted that NOACs alter this clinical equation because they offer predictable pharmacokinetics, eliminate the need for routine blood monitoring, and carry a lower risk of spontaneous intracranial hemorrhage compared to warfarin. Historically, physicians hesitated to prescribe blood thinners to elderly patients due to fall risks and bleeding concerns, but the neuroprotective profile of NOACs may shift those risk-benefit calculations.

Study authors noted limitations inherent to the design, emphasizing that because this is an observational study, it cannot establish direct cause and effect with absolute certainty. Unmeasured confounding factors and patient medication switches during follow-up could influence outcomes. Despite these caveats, researchers suggest that the ease of use of NOACs—free from the strict dietary rules and constant monitoring required by warfarin—helps support better adherence among patients experiencing cognitive impairment.

Frequently Asked Questions

What are NOACs?

NOACs stand for non-vitamin K antagonist oral anticoagulants, a newer class of blood-thinning medications used to prevent blood clots in patients with conditions like atrial fibrillation.

How do blood thinners affect Alzheimer’s disease?

According to the Karolinska Institutet study, newer blood thinners like NOACs are linked to a slower rate of cognitive decline in Alzheimer’s patients who also have atrial fibrillation, likely by reducing micro-strokes and improving cerebral blood flow.

Why are NOACs preferred over warfarin for some patients?

Experts note that NOACs offer predictable dosing without requiring routine blood monitoring or strict dietary limits, and they present a lower risk of major brain bleeding compared to warfarin.